NovoCure (NVCR) EBT Margin (2014 - 2026)

NovoCure (NVCR) posted EBT Margin of 6.78% for Q2 2026, up 82.95% sequentially from 39.79% in Q1 2026, and up 1524.0% YoY from 0.42% in Q2 2025.

NovoCure (NVCR) EBT Margin (2014 - 2026) Analysis & Trends

NovoCure has reported EBT Margin for 13 years, with the latest figure at 6.78% in Q2 2026.

Quarterly EBT Margin rose 1524.0% year-over-year to 6.78% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 21.84% (up 71.0% YoY) and the FY2025 annual result came in at 20.79%, up 88.0% from the prior year.
EBT Margin improved to 6.78% in Q2 2026 per NVCR's latest filing, from 39.79% in the prior quarter.
Over five years, EBT Margin peaked at 1.83% in Q1 2022 and troughed at 42.76% in Q2 2023.
A 5-year average of 23.81% and a median of 22.44% in 2024 frame the typical range for EBT Margin.
The sharpest annual moves came in 2023 and 2024: EBT Margin sank 3998 bps in 2023, then soared 2765 bps in 2024.
Over 5 years, EBT Margin stood at 25.35% in 2022, then decreased by 14 bps to 28.8% in 2023, then retreated by 19 bps to 34.23% in 2024, then soared by 31 bps to 23.49% in 2025, then soared by 71 bps to 6.78% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 6.78%, 39.79%, and 23.49% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Abbott Laboratories	199.61 Bn	194.01 Bn	7.27 Bn	12.10%
2	Stryker	127.81 Bn	124.34 Bn	4.50 Bn	23.74%
3	Medtronic	119.04 Bn	109.82 Bn	6.41 Bn	18.70%
4	Boston Scientific	73.68 Bn	73.14 Bn	3.85 Bn	19.48%
5	Edwards Lifesciences	51.96 Bn	47.71 Bn	1.35 Bn	29.86%
6	Dexcom	34.36 Bn	32.41 Bn	830.00 Mn	24.27%
7	GE HealthCare Technologies	33.83 Bn	31.72 Bn	2.18 Bn	13.09%
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	8.91%
9	Steris	23.06 Bn	22.58 Bn	684.20 Mn	18.32%
10	NovoCure	2.05 Bn	1.61 Bn	142.48 Mn	-6.78%

Download Data